ELIAS Animal Health, a US-based companion animal cancer therapeutics company, announced on Wednesday that it has named Brian Segebrecht as its new chief revenue officer.

In the new role, Segebrecht will head the commercialisation of the company's first-in-class adoptive cell therapy, and drive new business partnerships for the expanding product pipeline at ELIAS.

Segebrecht has most recently served as the CEO of Sentrx Animal Care.

Tammie Wahaus, ELIAS Animal Health CEO, said, 'Brian's track record of transforming commercial strategy and building value for shareholders make him the perfect fit as we move closer to the regulatory approval of ECI in Q4 of 2024. His leadership at ELIAS will be critical as we continue to pursue funding to support the commercialization of our lead product, as well as the continued expansion of our portfolio of companion animal cancer therapeutics.'